Trinomab Biotech is a clinical-stage Chinese biopharmaceutical company that operates globally. The firm is focused on advancing a product pipeline of therapeutic candidates. It recently completed a sizable pre-IPO financing to support those development efforts. The company raised about 750 million yuan (approximately $104.4 million) in the financing. Proceeds from the round are intended to advance its product pipeline and support ongoing clinical-stage activities. The article does not provide details on specific programs, revenues, or user metrics.

Total raised

$104M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2022